“Plants offer an enormous chemodiversity that is essential for discovering new medicines, with 25% of all FDA-approved drugs coming from plants. However, the production of plant-derived natural products faces significant challenges. Our research [explores] the biosynthesis and bioengineering of lyciumins and moroidins, two classes of branched cyclic peptides with potential pharmaceutical applications. Lyciumins, inhibitors of the human angiotensin-converting enzyme, come from the Goji berry, while moroidins, derived from the Australian stinging tree, exhibit anti-mitotic activities suitable for cancer therapy. … We propose to advance our understanding of RiPP diversity and biosynthesis, supporting new strategies for their engineering and application in medicine.”